As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.

Stopping GLP-1 RA treatment 14 days before total joint arthroplasty can minimize risks for complications, according to study findings.